Improvements in mucopolysaccharidosis I mice after adult retroviral Vector-mediated gene therapy with immunomodulation

Molecular Therapy

Volumn 15, Issue 5, 2007, Pages 889-902

  Ma, Xiucui ^a   Liu, Yuli ^a   Tittiger, Mindy ^a   Hennig, Anne ^a   Kovacs, Attila ^a   Popelka, Sarah ^a   Wang, Baomei ^a   Herati, Ramin ^a   Bigg, Mark ^a   Ponder, Katherine P ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; CD28 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; LEVO IDURONIDASE; OKT 4; RETROVIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA DISEASE; ARTICLE; BIOCHEMISTRY; BONE DISEASE; CONTROLLED STUDY; DISEASE RESISTANCE; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; HEARING; HURLER SYNDROME; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INHIBITION KINETICS; LYSOSOME STORAGE DISEASE; MOUSE; NEWBORN; NONHUMAN; SIGNAL TRANSDUCTION; SPLEEN; VIRAL GENE THERAPY; VISION;

ANIMALS; ANIMALS, NEWBORN; ANTIGENS, CD28; BETA-N-ACETYLHEXOSAMINIDASE; BONE AND BONES; BRAIN; FLOW CYTOMETRY; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; GLYCOSAMINOGLYCANS; HEARING; HUMANS; IDURONIDASE; IMMUNOCONJUGATES; LYSOSOMAL STORAGE DISEASES; LYSOSOMES; MICE; MICE, INBRED C57BL; MUCOPOLYSACCHARIDOSIS I; MYOCARDIUM; RETROVIRIDAE; SPLEEN; VISION;

MURINAE; MUS;

EID: 34247281922     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/sj.mt.6300112     Document Type: Article

References (46)

1. Neufeld, EF and Muenzer, J (2001). The mucopolysaccharidoses. In: Scriver, CR, Beaudet, AL, Sly, WS and Valle, D (eds). Metabolic and Molecular Basis of Inherited Disease. McGraw-Hill: New York, pp 3421-3452.
2. Lowry, RB, Applegarth, DA, Toone, JR, MacDonald, E and Thunem, NY (1990). An update on the frequency of mucopolysaccharide syndromes in British Columbia. Hum Genet 85: 389-390.
3. Zheng, Y, Rozengurt N, Ryazantsev, S, Kohn, DB, Satake, N and Neufeld, EF (2003). Treatment of the mouse model of mucopolysaccharidosis I with retrovirally transduced bone marrow. Mol Genet Metab 79: 233-244.
4. Breider, MA, Shull, RM and Constantopoulos, G (1989). Long-term effects of bone marrow transplantation in dogs with mucopolysaccharidosis I. Am J Pathol 134: 677-692.
5. Staba, SL, Escolar, ML, Poe, M, Kim, Y, Martin, PL, Szabolcs, P et al. (2004). Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N Engl J Med 350 1960-1969.
6. Desnick, RJ (2004). Enzyme replacement and enhancement therapies for lysosomal diseases. J Inherit Metab Dis 27: 385-410.
7. Kakkis, ED, Schuchman, E, He, X, Wan, Q, Kania, S, Wiemelt, S et al. (2001). Enzyme replacement therapy in feline mucopolysaccharidosis I. Mol Genet Metab 72: 199-208.
8. Kakkis, ED, McEntee, MF, Schmidtchen, A, Neufeld, EF, Ward, DA, Gompf, RE et al. (1996). Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem Mol Med 58: 156-167.
9. Kakkis, ED, Muenzer, J, Tiller, GE, Waber, L, Belmont, J, Passage, M et al. (2001). Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 344: 182-188.
10. Sands, MS and Davidson, BL (2006). Gene therapy for lysosomal storage diseases. Mol Ther 13: 839-849.
11. Hartung, SD, Frandsen, JL, Pan, D, Koniar, BL, Graupman, P, Gunther, R et al. (2004). Correction of metabolic, craniofacial, and neurologic abnormalilies in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene. Mol Ther 9: 866-875.
12. Liu, Y, Xu, L, Hennig, AK, Kovacs, A, Fu, A, Chung, S et al. (2005). Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice. Mol Ther 11: 35-47.
13. Chung, S, Ma, X, Liu, Y, Lee, D, Tittiger, ME and Ponder, KP (2007). Effect of neonatal administration of a retroviral vector expressing α-L iduronidase upon lysosomal storage in brain and other organs in mucopolysaccharidosis I mice. Mol Genet Metab 90: 181-192
14. Kobayashi, H, Carbonaro, D, Pepper, K, Petersen, D, Ge, S, Jackson, H et al. (2005). Neonatal gene therapy of MPS I mice by intravenous injection of a lentiviral vector. Mol Ther 11: 776-789.
15. Di Domenico, C, Villani, GR, Di Napoli, D, Reyero, EG, Lombardo, A, Naldini, L et al. (2005). Gene therapy for a mucopolysaccharidosis type I murine model with lentiviral-IDUA vector. Hum Gene Ther 16: 81-90.
16. Lutzko, C, Kruth, S, Abrams-Ogg, AC, Lau, K, Li, L, Clark, BR et al. (1999). Genetically corrected autologous stem cells engraft but host immune responses limit their utility in canine alpha-L-iduronidase deficiency. Blood 93: 1895-1905.
17. Domenico, CD, Napoli, DD, Reyero, EG, Lombardo, A, Naldini, L and Natale, PD (2006). Limited transgene immune response and long-term expression of human alpha-L-iduronidase in young adult mice with mucopolysaccharidosis type I by liver-directed gene therapy. Hum Gene Ther 17: 1112-1121.
18. Snanoudj R, de Preneuf, H, Creput, C, Arzouk, N, Deroure, B, Beaudreuil, S et al. (2006). Costimulation blockade and its possible future use in clinical transplantation. Transpl Int 19: 693-704.
19. Kosuga, M, Takahashi, S, Sasaki, K, Li, XK, Fujino, M, Hamada, H et al. (2000). Adenovirus-mediated gene therapy for mucopolysaccharidosis VII: Involvement of cross-correction in wide-spread distribution of the gene products and long-term effects of CTLA-4lg coexpression. Mol Ther 1: 406-413.
20. Ponder, KP, Wang, B, Wang, P, Ma, X, Herati, R, Wang, B et al. (2006). Mucopolysaccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-lg. Mol Ther 14: 5-13.
21. Stein, CS, Ghodsi, A, Derksen, T and Davidson, BL (1999). Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice. J Virol 73: 3424-3429.
22. Miao, CH, Ye, P, Thompson, AR, Rawlings, DJ and Ochs, HD (2006). Immunomodulation of transgene responses following naked DNA transfer of human factor VIII into hemophilia A mice. Blood 108: 19-27.
23. Zhan, Y, Brown, LE, Deliyannis, G, Seah, S, Wijburg, OL, Price, J et al. (2004). Responses against complex antigens in various models of CD4 T-cell deficiency: Surprises from an anti-CD4 antibody transgenic mouse. Immunol Res 30: 3-14.
24. Ross, CJ, Bastedo, L, Maier, SA, Sands, MS and Chang, PL (2000). Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells. Hum Gene Ther 11: 2117-2127.
25. Kakkis, E, Lester, T, Yang, R, Tanaka, C, Anand, V, Lemontt, J et al. (2004). Successful induction of immune tolerance to enzyme replacement therapy in canine mucopolysaccharidosis I. Proc Natl Acad Sci USA 101: 829-834.
26. Xu, L, Mango, RL, Sands, MS, Haskins, ME, Ellinwood, NM and Ponder, KP (2002). Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy. Mol Ther 6: 745-758.
27. Bunge, S, Clements, PR, Byers, S, Kleijer, WJ, Brooks, DA and Hopwood, JJ (1998). Genotype-phenotype correlations in mucopolysaccharidosis type I using enzyme kinetics, immunoquantification and in vitro turnover studies. Biochim Biophys Acta 1407: 249-56.
28. Ohlemiller, KK, Vogler, CA, Roberts, M, Galvin, N and Sands, MS (2000). Retinal function is improved in a murine model of a lysosomal storage disease following bone marrow transplantation. Exp Eye Res 71 469-481.
29. Brown, BD, Venneri, MA, Zingale, A, Sergi, L and Naldini, L (2006). Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 12: 585-591.
30. Ohlemiller, KK, Hennig, AK, Lett, JM, Heidbreder, AF and Sands, MS (2002). Inner ear pathology in the mucopolysaccharidosis VII mouse. Hear Res 169: 69-84.
31. Vogler, C, Levy, B, Grubb, JH, Galvin, N, Tan, Y, Kakkis, E et al. (2005). Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc Natl Acad Sci USA 102: 14777-14782.
32. Kawai, T, Andrews, D, Colvin, RB, Sachs, DH and Cosimi, AB (2000). Thromboembolic: Complications after treatment with monoclonal antibody against CD40 ligand. Nat Med 6: 114.
33. Adams, AB, Shirasugi, N, Jones, TR, Durham, MM, Strobert, EA, Cowan, S et al. (2005). Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y th prolong islet allograft survival. J Immunol 174: 542-550.
34. Winsor-Hines, D, Merrill, C, O'Mahony, M, Rao, PE, Cobbold, SP, Waldmann, H et al. (2004). Induction of immunological tolerance/ hyporesponsiveness in baboons with a nondepleting CD4 antibody. J Immunol 173: 4715-4723.
35. Themis, M, Waddington, SN, Schmidt M, von Kalle, C, Wang, Y, Al-Allaf, F et al. (2005). Oncogenesis following delivery of a nonprimate lentiviral gene therapy vector to fetal and neonatal mice. Mol Ther 12: 763-771.
36. Nienhuis, AW, Dunbar, CE and Sorrentino, BP (2006). Genotoxicity of retroviral integration in hematopoietic cells. Mol Ther 13: 1031-1049.
37. Gao, C, Jokerst, R, Gondipalli, P, Cai, SR, Kennedy, S, Flye, MW et al. (1999). Lipopolysaccharide potentiates the effect of hepatocyte growth factor on hepatocyte replication in rats by augmenting AP-1 activity. Hepatology 30: 1405-1416.
38. Ohmi, K, Greenberg, DS, Rajavel, KS, Ryazantsev, S, Li, HH and Neufeld, EF (2003). Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci USA 100 1902-1907.
39. Martin, P, del Hoyo, GM, Anjuere, F, Ruiz, SR, Arias, CF, Marin, AR et al. (2000). Concept of lymphoid versus myeloid dendritic cell lineages revisited: Both CD8alpha (-) and CD8alpha(+) dendritic cells are generated from CD4(low) lymphoid-committed precursors. Blood 96: 2511-2519.
40. Miga, AJ, Masters, SR, Durell, BG, Gonzalez, M, Jenkins, MK, Maliszewski, C et al. (2001). Dendritic cell longevity and T cell persistence is controlled by CD154-CD40 interactions. Eur J Immunol 31: 959-965.
41. Hennig, AK, Ogilvie, JM, Ohlemiller, KK, Timmers, AM, Hauswirth, WW and Sands, MS (2004). AAV-mediated intravitreal gene therapy reduces lysosomal storage in the retinal pigmented epithelium and improves retinal function in adult MPS VII mice.Mol Ther 10: 106-116.
42. 4 monoclonal antibody in dilated cardiomyopathy mice. J Clin Immunol 25: 376-384.
43. Overbergh, L, Giulietti, A, Valckx, D, Decallonne, B, Bouillon, R and Mathieu, C (2003). The use of real-time reverse transcriptase PCR for the quantification of cytokine gene expression. J Biomol Tech 14: 33-43.
44. Zhang, J, Xu, L, Haskins, ME and Ponder, KP (2004). Neonatal gene transfer with a retroviral vector results in tolerance to human factor IX in mice and dogs. Blood 103: 143-151.
45. Wang, B, O'Malley, TM, Xu, L, Vite, C, Wang, P, O'Donnell, PA et al. (2006). Expression in blood cells may contribute to biochemical and pathological improvements after neonatal intravenous gene therapy for mucopolysaccharidosis VII in dogs. Mol Genet Metab 87: 8-21.
46. Donnelly, RA (2004). Correlation and simple regression. In: The Complete Idiot's Guide to Statistics. Penguin Group: New York. pp 293-314.